アンジオテンシンII型1受容体阻害は致死性悪性高血圧を予防する:腎臓炎症との関連
K F Hilgers1, A Hartner, M Porst
1Department of Medicine IV, University of Erlangen, Nürnberg, Germany. karl.hilgers@rzmail.uni-erlangen.de
Circulation
|September 19, 2001
まとめ
ヴァルサルタンによるアニオテンシンII型1受容体阻害は,血圧を下げなくても致命的な悪性高血圧を予防します. これは,アンジオテンシンIIを阻害することを示唆しています.
科学分野:
- ネフロロジーはネフロロジーを用います.
- 心血管研究 循環器科の研究
- 薬理学 薬理学とは
背景:
- 悪性高血圧は,アンジオテンシンII濃度の上昇と関連しています.
- この研究は,悪性高血圧の予防におけるアニオテンシンII型1受容体阻害の役割を調査しています.
研究 の 目的:
- アンジオテンシンII型1受容体阻害が悪性高血圧を予防するかどうかを,血圧低下効果とは無関係にテストする.
- アンジオテンシンII型1受容体阻害の保護効果の背後にある潜在的なメカニズムを探求する.
主な方法:
- 2つの腎臓,1クリップのラットモデルによる腎血管高血圧.
- ヴァルサルタン (選択的アニオテンシンII型1受容体阻害剤) を2つの異なる用量または溶媒で投与する.
- テイル・マンフット・プレチスモグラフィーおよび動脈内測定による血圧のモニタリング.
- 悪性腎硬化症に対する組織学的検査と炎症マーカーの評価 (単細胞化学吸引タンパク質-1,マクロファージの流入).
主要な成果:
- 低用量と高用量のヴァルサルタンの両方が致死性悪性高血圧を予防し,溶媒群は高い死亡率を示した.
- バルサータンの高用量のみが血圧を著しく低下させた.
- バルサルタン治療は,血圧の変化に関係なく,悪性腎硬化症の組織学的徴候を予防し,腎臓の炎症マーカーを減少させた.
- 溶剤で治療されたラットは,単細胞化学誘導タンパク質-1の発現と腎臓にマクロファージの浸透が増加した.
結論:
- バルサルタンによるアニオテンシンII型1受容体阻害は,血圧低下とは関係なく,致命的な悪性高血圧を効果的に予防します.
- ヴァルサルタンの腎臓における抗炎症効果は,悪性高血圧に対する保護的役割に寄与する可能性がある.
- アンジオテンシンIIシグナル伝達経路をターゲットにすることは,重度の高血圧状態の管理のための潜在的な治療戦略を提供します.
関連する概念動画
Antihypertensive Drugs: Action of β1 Blockers
2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.8K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.8K
Hypertension II: Pathophysiology
1.8K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.8K


